Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286058 | 0.91 | TSHR (0.39) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL17233403 | 0.88 | TSHR (0.46) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL15453370 | 0.82 | MGAM (0.48) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL13435347 | 0.82 | TSHR (0.40) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL16314979 | 0.80 | TSHR (0.50) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL594992 | 0.80 | TSHR (0.46) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL15453519 | 0.80 | TSHR (0.45) | TSHRTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1132780 | 0.80 | TSHR (0.39) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL4691009 | 0.79 | TSHR (0.43) | TSHRTP53HSD17B10MGAMGAA | |
| SCHEMBL15453486 | 0.78 | TP53 (0.37) | TSHRTP53HSD17B10MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383547-B2 | Methods of treatment for a kidney disease | VANDERBILT UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| CN-118056836-A | Substituted aminopyrimidine macrocyclic compound, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-05-21 | — | — | CN | disclosed |
| US-20230310411-A1 | METHODS OF TREATMENT FOR A KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-05 | — | — | US | disclosed |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| CN-114173787-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 杨森科学爱尔兰无限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| EP-0500360-B1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-06-25 | — | — | EP | disclosed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| EP-0480708-B1 | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1995-10-11 | — | — | EP | disclosed |
| US-5428033-A | Useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotecyive agents | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| US-5266568-A | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-11-30 | — | — | US | disclosed |
| US-5212180-A | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-05-18 | — | — | US | disclosed |
| EP-0500360-A1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-08-26 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | TSHR 4786/4885TP53 3199/4885HSD17B10 442/4885 |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | TSHR 3970/4885TP53 279/4885HSD17B10 1034/4885 |
| US-20230310411-A1 | METHODS OF TREATMENT FOR A KIDNEY DISEASE | LTB4R2, LTB4R, ALOX5 | TSHR 1743/4885TP53 4829/4885HSD17B10 1107/4885 |
| US-12383547-B2 | Methods of treatment for a kidney disease | LTB4R2, LTB4R, ALOX5 | TSHR 1743/4885TP53 4829/4885HSD17B10 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.